The end of 2024 brought near-term cash shortfalls into focus at several biopharmaceutical companies, while others completed their assessments of potential alternatives to shutting their doors as capital dwindled. Vincerx Pharma and Achilles Therapeutics wrapped up strategic reviews with transactions announced in late December, while Viracta Therapeutics said it closed the pivotal Phase II study for its last remaining clinical-stage asset to conserve cash.
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options
Workforce Reductions At Outlook, Editas, Cellectar
Restructuring Edition: Vincerx strategic review ends with a merger, Viracta halts last clinical trial and assesses options, and Achilles completed a strategic review by selling assets to AstraZeneca. Also, Synaptogenix explores opportunities, while GenSight warns its cash is running out.
More from Finance Watch
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.